Decision on Rights Offering via Debt-to-Equity Swap Following Rehabilitation Plan Approval (Debt Repayment Purpose, Expected Change of Largest Shareholder)

UNION KOREA PHARM received court approval for a rehabilitation plan on May 12, 2026.
Sequentially implementing debt-to-equity swap (effective May 19), capital reduction/merge (May 27), and third-party allotment rights offering (May 28) per the plan.
The rights offering is for debt repayment via debt-to-equity conversion, not new capital raising.
Expected change of largest shareholder.
No new cash injection; in-kind contribution is debt repayment.
Fractional shares will be cancelled; total shares and capital may change.
Listing date of new shares subject to change based on court decisions and procedures.